SCHEMBL493301

SCHEMBL493301

CN(C)C(c1ccc(F)cc1)C1CCC(NC(=O)COC2CCN(S(=O)(=O)c3ccc(Cl)cc3Cl)C2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
EPHX2 P34913 3/20 0.41
TRPV4 Q9HBA0 2/20 0.41
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
MAPT P10636 2/20 0.40
NPY1R P25929 1/20 0.40
NPY2R P49146 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HTT P42858 1/20 0.39
ALDH1A1 P00352 7/20 0.39
KDM4E B2RXH2 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.38
POLB P06746 1/20 0.38
RAB9A P51151 1/20 0.38
PKM P14618 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
NOD2 Q9HC29 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL493966 0.93 ALDH1A1 (0.40) LMNASMN1; SMN2TRPV4KMT2AMEN1
SCHEMBL493009 0.92 EPHX2 (0.40) LMNASMN1; SMN2EPHX2TRPV4KMT2A
SCHEMBL493220 0.90 TRPV4 (0.40) LMNASMN1; SMN2EPHX2TRPV4KMT2A
SCHEMBL492814 0.89 PKM (0.44) LMNASMN1; SMN2EPHX2KMT2AMEN1
SCHEMBL493091 0.89 TRPV4 (0.39) LMNASMN1; SMN2EPHX2TRPV4KMT2A
SCHEMBL493342 0.87 PKM (0.48) LMNASMN1; SMN2EPHX2KMT2AMEN1
SCHEMBL493187 0.85 PKM (0.44) EPHX2KMT2AMEN1MAPTALDH1A1
SCHEMBL493537 0.84 EPHX2 (0.41) LMNASMN1; SMN2EPHX2KMT2AMEN1
SCHEMBL492924 0.84 PKM (0.47) LMNASMN1; SMN2EPHX2KMT2AMEN1
SCHEMBL493757 0.83 KMT2A (0.39) LMNASMN1; SMN2EPHX2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106055-B2 Substituted amide compounds GRUENENTHAL GMBH (DE) 2012-01-31 US claimed
EP-2139851-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-01-06 EP claimed
US-20080306084-A1 Substituted Amide Compounds GRUENENTHAL GMBH (DE) 2008-12-11 US claimed
WO-2008131946-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO claimed
US-8106055-B2 Substituted amide compounds GRUENENTHAL GMBH (DE) 2012-01-31 US disclosed
EP-2139851-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-01-06 EP disclosed
US-20080306084-A1 Substituted Amide Compounds GRUENENTHAL GMBH (DE) 2008-12-11 US disclosed
WO-2008131946-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306084-A1 Substituted Amide Compounds OPRK1, NAA50, ACMSD LMNA 2485/4885SMN1; SMN2 1729/4885EPHX2 2567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.